Zepteon is a cutting-edge brand revolutionizing the field of antibodies. As a privately held corporation, Zepteon has developed innovative chromatography resins that have the remarkable ability to separate antibodies and Fc-fusions with specific glycoforms. These glycoforms have the potential to more effectively combat infectious diseases, cancer, autoimmunity, and rare diseases.

With the goal of advancing transformative medicines, Zepteon's technology is instrumental in streamlining the development of Biosimilars, enhancing the effectiveness of Biobetters, and enabling the creation of novel plasma-derived therapeutics (IVIG). Established in 2012, Zepteon has made significant strides since spinning out of a large pharmaceutical company. They have successfully launched Glycap-3A chromatography resin, garnered a substantial customer base, and obtained patents in the US, EU, and other regions, including the US10221210B2 and EP2734537A1 patents.

Led by an extraordinary team, including CEO Austin Boesch and COO Glen Bolton, who have extensive R&D experience in the biopharmaceutical field, Zepteon is at the forefront of pioneering advancements in antibody technologies. With their wealth of expertise and numerous publications and patents, Zepteon is poised to revolutionize the future of antibody research and production